LBGI and GRADE (hypoglycemia) were studied to be lower in the quadruple therapy group (0.25 ± 0.41, 0.77 ± 1.73) and higher in SGLT2 inhibitors monotherapy group (1.17 ± 1.08, 10.54 ± 16.68). The gene discussed is SLC5A2; the disease is Hypoglycemia.